BACKGROUND: Vancomycin-resistant Enterococcus (VRE) bloodstream infections (BSIs) are associated with increased morbidity and mortality. OBJECTIVE: To determine the hospital costs and length of stay attributable to VRE BSI and vancomycin-sensitive Enterococcus (VSE) BSI and the independent effect of vancomycin resistance on hospital costs. METHODS: A retrospective cohort study was conducted of 21,154 nonsurgical patients admitted to an academic medical center during the period from 2002 through 2003. Using administrative data, attributable hospital costs (adjusted for inflation to 2007 US dollars) and length of stay were estimated with multivariate generalized least-squares (GLS) models and propensity score-matched pairs. RESULTS: The cohort included 94 patients with VRE BSI and 182 patients with VSE BSI. After adjustment for demographics, comorbidities, procedures, nonenterococcal BSI, and early mortality, the costs attributable to VRE BSI were $4,479 (95% confidence interval [CI], $3,500-$5,732) in the standard GLS model and $4,036 (95% CI, $3,170-$5,140) in the propensity score-weighted GLS model, and the costs attributable to VSE BSI were $2,250 (95% CI, $1,758-$2,880) in the standard GLS model and $2,023 (95% CI, $1,588-$2,575) in the propensity score-weighted GLS model. The median values of the difference in costs between matched pairs were $9,949 (95% CI, $1,579-$24,693) for VRE BSI and $5,282 (95% CI, $2,042-$8,043) for VSE BSI. The costs attributable to vancomycin resistance were $1,713 (95% CI, $1,338-$2,192) in the standard GLS model and $1,546 (95% CI, $1,214-$1,968) in the propensity score-weighted GLS model. Depending on the statistical method used, attributable length of stay estimates ranged from 2.2 to 3.5 days for patients with VRE BSI and from 1.1 to 2.2 days for patients with VSE BSI. CONCLUSIONS: VRE BSI and VSE BSI were independently associated with increased hospital costs and increased length of stay. Vancomycin resistance was associated with increased costs.
BACKGROUND:Vancomycin-resistant Enterococcus (VRE) bloodstream infections (BSIs) are associated with increased morbidity and mortality. OBJECTIVE: To determine the hospital costs and length of stay attributable to VRE BSI and vancomycin-sensitive Enterococcus (VSE) BSI and the independent effect of vancomycin resistance on hospital costs. METHODS: A retrospective cohort study was conducted of 21,154 nonsurgical patients admitted to an academic medical center during the period from 2002 through 2003. Using administrative data, attributable hospital costs (adjusted for inflation to 2007 US dollars) and length of stay were estimated with multivariate generalized least-squares (GLS) models and propensity score-matched pairs. RESULTS: The cohort included 94 patients with VRE BSI and 182 patients with VSE BSI. After adjustment for demographics, comorbidities, procedures, nonenterococcal BSI, and early mortality, the costs attributable to VRE BSI were $4,479 (95% confidence interval [CI], $3,500-$5,732) in the standard GLS model and $4,036 (95% CI, $3,170-$5,140) in the propensity score-weighted GLS model, and the costs attributable to VSE BSI were $2,250 (95% CI, $1,758-$2,880) in the standard GLS model and $2,023 (95% CI, $1,588-$2,575) in the propensity score-weighted GLS model. The median values of the difference in costs between matched pairs were $9,949 (95% CI, $1,579-$24,693) for VRE BSI and $5,282 (95% CI, $2,042-$8,043) for VSE BSI. The costs attributable to vancomycin resistance were $1,713 (95% CI, $1,338-$2,192) in the standard GLS model and $1,546 (95% CI, $1,214-$1,968) in the propensity score-weighted GLS model. Depending on the statistical method used, attributable length of stay estimates ranged from 2.2 to 3.5 days for patients with VRE BSI and from 1.1 to 2.2 days for patients with VSE BSI. CONCLUSIONS: VRE BSI and VSE BSI were independently associated with increased hospital costs and increased length of stay. Vancomycin resistance was associated with increased costs.
Authors: Adam L Cohen; David Calfee; Scott K Fridkin; Susan S Huang; John A Jernigan; Ebbing Lautenbach; Shannon Oriola; Keith M Ramsey; Cassandra D Salgado; Robert A Weinstein Journal: Infect Control Hosp Epidemiol Date: 2008-10 Impact factor: 3.254
Authors: Jonas Marschall; Leonard A Mermel; David Classen; Kathleen M Arias; Kelly Podgorny; Deverick J Anderson; Helen Burstin; David P Calfee; Susan E Coffin; Erik R Dubberke; Victoria Fraser; Dale N Gerding; Frances A Griffin; Peter Gross; Keith S Kaye; Michael Klompas; Evelyn Lo; Lindsay Nicolle; David A Pegues; Trish M Perl; Sanjay Saint; Cassandra D Salgado; Robert A Weinstein; Robert Wise; Deborah S Yokoe Journal: Infect Control Hosp Epidemiol Date: 2008-10 Impact factor: 3.254
Authors: E N Vergis; M K Hayden; J W Chow; D R Snydman; M J Zervos; P K Linden; M M Wagener; B Schmitt; R R Muder Journal: Ann Intern Med Date: 2001-10-02 Impact factor: 25.391
Authors: Robert K Pelz; Pamela A Lipsett; Sandra M Swoboda; Marie Diener-West; Neil R Powe; Roy G Brower; Trish M Perl; Janet M Hammond; Craig W Hendrix Journal: Intensive Care Med Date: 2002-04-12 Impact factor: 17.440
Authors: Matthew Kelly; Margaret Conway; Kathleen Wirth; Gail Potter-Bynoe; Amy L Billett; Thomas J Sandora Journal: Infect Control Hosp Epidemiol Date: 2011-09-20 Impact factor: 3.254
Authors: Erika M C D'Agata; Diana Tran; Josef Bautista; Douglas Shemin; Daniel Grima Journal: Clin J Am Soc Nephrol Date: 2018-08-23 Impact factor: 8.237
Authors: S M McGlone; R R Bailey; S M Zimmer; M J Popovich; Y Tian; P Ufberg; R R Muder; B Y Lee Journal: Clin Microbiol Infect Date: 2011-06-10 Impact factor: 8.067
Authors: Adam J DiPippo; Frank P Tverdek; Jeffrey J Tarrand; Jose M Munita; Truc T Tran; Cesar A Arias; Samuel A Shelburne; Samuel L Aitken Journal: J Infect Date: 2016-11-11 Impact factor: 6.072
Authors: Mandy Bodily; Kathleen M McMullen; Anthony J Russo; Nupur D Kittur; Joan Hoppe-Bauer; David K Warren Journal: Infect Control Hosp Epidemiol Date: 2013-06-27 Impact factor: 3.254
Authors: S M Bartsch; J A McKinnell; L E Mueller; L G Miller; S K Gohil; S S Huang; B Y Lee Journal: Clin Microbiol Infect Date: 2016-09-15 Impact factor: 8.067